Erind Alushaj on Muck Rack

Erind Alushaj

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Erind

Contact Erind, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Infographic: teprotumumab for the treatment of active thyroid eye disease

|
By Erind Alushaj, Michael Lowe, Susan P Mollan, Sarah Simpson, Gabriele Berman
| Nature Verified
Fig. 1 Teprotumumab is a monoclonal antibody therapy targeting insulin-like growth factor-1 receptor (IGF-IR) for thyroid eye disease (TED). Teprotumumab is an alternative to traditional immunosuppression [1, 2]. This infographic summarises the design and results of the multicentre phase III “OPTIC” trial: Treatment of Graves’ Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis with Protumumab Infusions in a Randomized, Placebo-Controlled, Trial, Investigating Clinical Efficacy.
Open in Who Shared Issue with article?

Infographic: Teprotumumab for thyroid-associated ophthalmopathy - Eye

|
By Erind Alushaj, Gabriele Berman, Susan P Mollan, Sarah Simpson, Michael Lowe
| Nature Verified
Fig. 1 Teprotumumab is a targeted monoclonal antibody therapy for thyroid-associated ophthalmopathy (TAO), offering an alternative to traditional immunosuppressive approaches with notable side effect profiles [1,2,3]. This infographic summarises the design and results of the pivotal phase II trial confirming its efficacy.
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified